Glaukos Corporation · NYSE:GKOS
Glaukos — Investor Presentation (May 2020)
27 slides from Glaukos's investor presentation, May 11, 2020
Slide 1: May 2020
1 © 2020 Glaukos Corporation 1 May 2020
Slide 2: Disclaimer
2 © 2020 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are ba
Slide 3: Building a World-Class Global Infrastructure & Company
3 © 2020 Glaukos Corporation 1 FY2014 sales; FY2019 sales; 2 FY2014 gross margin; FY2019 non-GAAP gross margin; 3 2015 as of 6/30/2015 (post-IPO); 2019 as of 12/31/2019; 4 12/31/2019 includes former Avedro employees Building a World-Class Global Infrastructure & Company Significant Progress Since 20
Slide 4: 2019: Major Achievements that Strengthened Our Long-Term Growth Potential
4 © 2020 Glaukos Corporation 2019: Major Achievements that Strengthened Our Long-Term Growth Potential… Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2019 Completed acquisition, establishing Corneal Health franchise Strengthened US market leadership with successful launch Completed acquisition to
Slide 5: Transforming the treatment of chronic eye diseases
5 © 2020 Glaukos Corporation Transforming the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs
Slide 6: Leveraging Our Core Competencies to Build & Disrupt Major Ophthalmic Markets
6 © 2020 Glaukos Corporation MAJOR PATIENT POPULATIONS DELIVER safe, effective therapies that optimize vision care and build durable franchises to serve doctors and patients Leveraging Our Core Competencies to Build & Disrupt Major Ophthalmic Markets Creating a Unique Vision Care Leader to Drive Lon
Slide 7: Glaucoma
7 © 2020 Glaukos Corporation Glaucoma
Slide 8: Glaucoma Overview
8 © 2020 Glaukos Corporation Glaucoma Overview Chronic Disease is Second-Leading Cause of Blindness Worldwide Glaucoma Portfolio1 Micro-Surgical Devices Sustained Pharmaceuticals Implantable Biosensors iStent® iStent inject® Santen Preserflo™ iStent infinite™ iStent® SA iDose® TR iDose® TREX iDose®
Slide 9: Glaucoma Micro-Surgical Devices
9 © 2020 Glaukos Corporation Glaucoma Micro-Surgical Devices Industry’s Most Comprehensive Offering Designed to Address Full Range of Disease Progression Approved 2018 2 multi-directional trabecular meshwork stents in auto injection system Approval Target 2021 3 multi-directional trabecular meshwork
Slide 10: Glaucoma Sustained Pharmaceuticals
10 © 2020 Glaukos Corporation Glaucoma Sustained Pharmaceuticals Designed to Be Viable Alternative to Topical Medications, Addressing Non-Adherence and Other Drawbacks INTENDED DISEASE STATE Ocular Hypertension to Moderate OAG Titanium implant designed for continuous drug delivery directly into ante
Slide 11: Next-Generation iDose TREX
11 © 2020 Glaukos Corporation Glaucoma Sustained Pharmaceuticals Next-Generation iDose TREX Designed for Increased Drug Payload & Duration-of-Effect INTENDED DISEASE STATE Ocular Hypertension to Moderate OAG Substantial increase in drug payload, with potential to double the duration-of-effect vs fir
Slide 12: Potential to Leverage iDose Platform with Novel ROCK Inhibitor Compounds
12 © 2020 Glaukos Corporation Glaucoma Sustained Pharmaceuticals Potential to Leverage iDose Platform with Novel ROCK Inhibitor Compounds iDose Rock is not approved by the FDA R&D teams focused on drug characteristics and predictability for delivery via iDose system Small-molecule APIs, high potency
Slide 13: Glaucoma Summary
13 © 2020 Glaukos Corporation PRE-CLINICAL INITIAL TRIAL PIVOTAL TRIAL FDA SUBMISSION APPROVAL / TARGET IOP Sensor Glaucoma Summary Glaucoma Portfolio Micro-Surgical Devices Sustained Pharmaceuticals PRE-CLINICAL INITIAL TRIAL PIVOTAL TRIAL FDA SUBMISSION APPROVAL / TARGET iStent 2012 iStent inject
Slide 14: Corneal Health
14 © 2020 Glaukos Corporation Corneal Health
Slide 15: Corneal Health Overview
15 © 2020 Glaukos Corporation Corneal Health Overview Focused on Disruptive Solutions Across Keratoconus, Presbyopia & Dry Eye Patient Populations Corneal Health Portfolio Sustained Pharmaceuticals iLink For Keratoconus Photrexa® Epi-off Epi-on iLink For Presbyopia PiXL™ For Dry Eye Intratus 1.1M Ey
Slide 16: Recently Completed Avedro Acquisition
16 © 2020 Glaukos Corporation Corneal Health Recently Completed Avedro Acquisition Sets Cornerstone for New Corneal Health Franchise STATUS Perfect commercial fit Accelerates growth trajectory Furthers hybrid pharma strategy Enhances organic pipeline initiatives/R&D teams Creates shareholder value S
Slide 17: Photrexa Therapy: First Bio-Activated Drug for Anterior Segment Disease
17 © 2020 Glaukos Corporation Removing the epithelium (Epi-off only) Single application of Photrexa® & Photrexa® Viscous applied to cornea UV illumination is applied Patient cornea post treatment Photrexa Therapy: First Bio-Activated Drug for Anterior Segment Disease Photrexa Epi-off is First FDA-Ap
Slide 18: Epi-on Therapy
18 © 2020 Glaukos Corporation Epi-on Therapy Non-Invasive Therapy Offers Potential to Expand Keratoconus Treatment Population Designed to reduce treatment time and complexity; improves patient comfort and faster recovery; expected to drive increased willingness to treat patients earlier • Involves a
Slide 19: PiXL Therapy for Presbyopia & Low Myopia
19 © 2020 Glaukos Corporation CENTRAL ACTIVATION FOR MYOPIA PERIPHERAL ACTIVATION FOR PRESBYOPIA 4 Single-application of bio-activated topical ophthalmic pharmaceuticals as a potential alternative to LASIK, refractive IOLs or implants Potential to provide spectacle independence with minimal compromi
Slide 20: Intratus Topical Therapy for Dry Eye & Corneal Disorders
20 © 2020 Glaukos Corporation Intratus Topical Therapy for Treatment of Dry Eye & Corneal Disorders Proprietary lotion applied to outer skin surface of the upper eyelids Anatomy of the eyelid with targeted sites Novel, sustained pharmaceutical platform targeting dry eye and other ocular disorders Pa
Slide 21: Corneal Health Summary
21 © 2020 Glaukos Corporation Corneal Health Summary Corneal Health Portfolio Sustained Pharmaceuticals PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 FDA SUBMISSION APPROVAL / TARGET Keratoconus Photrexa Epi-off 2016 Epi-on 2022 Presbyopia PiXL Dry Eye Intratus +X.X FDA approval targets subject to potential
Slide 22: Retinal Disease
22 © 2020 Glaukos Corporation Retinal Disease
Slide 23: Retinal Disease
23 © 2020 Glaukos Corporation Retinal Disease Portfolio Sustained Pharmaceuticals Triamcinolone Acetonide Anti-VEGF Biologic Multi-Kinase Inhibitor 29M People in the US have retinal disease1 • AMD and diabetic eye disease make up 89% of all retinal disease and are leading causes of blindness • AMD a
Slide 24: Sustained Release Candidate for DME Shows Early Promise
24 © 2020 Glaukos Corporation Retinal Disease Programs Sustained Release Candidate for DME Shows Early Promise Triamcinolone Acetonide Formulations developed to release triamcinolone acetonide for up to 6 months Comparison of Glaukos triamcinolone acetonide implant with typical intravitreal implants
Slide 25: Two Sustained Release Candidates for Wet AMD Under Development
25 © 2020 Glaukos Corporation Retinal Disease Programs Two Sustained Release Candidates for Wet AMD Under Development Anti-VEGF Biologic Developing sustained release, hydrogel-based, erodible implant with protein stabilization technology Release rate of anti-VEGF protein verified in animal model of
Slide 26: Creating a Unique Vision Care Leader
26 © 2020 Glaukos Corporation MARKET OPPORTUNITY 2015-2019 2020-22 2023-24 2025+ Creating a Unique Vision Care Leader Moving Beyond Combo-Cataract MIGS to Drive Long-Term Growth & Profitability iStent (cc) iStent inject (cc) Photrexa Epi-off Preserflo iStent infinite Epi-on iDose TR iDose Rock IOP S
Slide 27: 27 © 2020 Glaukos Corporation 2 7
27 © 2020 Glaukos Corporation 2 7